The role of Acinetobacter baumannii in infectious pathology (literature review)

A. O. Golubeva; A. P. Bondarenko; O. E. Trotsenko; O. N. Ogienko

doi:10.36604/1998-5029-2025-97-160-177

The role of Acinetobacter baumannii in infectious pathology (literature review)

A. O. Golubeva, A. P. Bondarenko, O. E. Trotsenko, O. N. Ogienko

https://doi.org/10.36604/1998-5029-2025-97-160-177

Full Text:

PDF (Rus)

Generate QR code

Abstract

Acinetobacter baumannii is one of the most frequently detected infectious agents worldwide, the important features of which are a high mutation rate, leading to the rapid development of antibiotic resistance, and resistance to disinfection. This review presents information on the significance of this pathogen in infectious pathology, the mechanisms underlying diseases associated with A. baumannii, virulence factors, multiple drug resistance of the pathogen, its resistance to aggressive environmental factors, the methods used by the pathogen to colonize and infect the human body, risk factors for infection, and clinical forms of the diseases it causes. The choice of drugs for the treatment of infections caused by A. baumannii is discussed. A search and analysis of scientific publications was carried out using electronic library search systems – eLIBRARY.ru, PubMed, Google Scholar, CyberLeninka

Keywords

non-fermentative gram-negative bacteria, Acinetobacter baumannii, clinical manifestations, hospital-acquired infection, detection rate, virulence factors, multidrug resistance

About the Authors

A. O. Golubeva

Federal Budgetary Institution of Science "Khabarovsk Scientific Research Institute of Epidemiology and Microbiology" of the Federal Service for Supervision of Consumer Rights Protection and Human Well-being
Russian Federation

Aleksandra O. Golubeva, Junior Staff Scientist, Laboratory of Bacterial Infections, Federal Budgetary Institution of Science "Khabarovsk Scientific Research Institute of Epidemiology and Microbiology"

2 Shevchenko Str., Khabarovsk, 680000

A. P. Bondarenko

Albina P. Bondarenko, MD, PhD (Med.), Leading Staff Scientist, Head of Laboratory of Bacterial Infections

2 Shevchenko Str., Khabarovsk, 680000

O. E. Trotsenko

Olga E. Trotsenko, MD, PhD, DSc (Med.), Director

2 Shevchenko Str., Khabarovsk, 680000

O. N. Ogienko

Olga N. Ogienko, Junior Staff Scientist, Laboratory of Bacterial Infections

2 Shevchenko Str., Khabarovsk, 680000

References

1. Skurikhina Yu.E., Turkutyukov V.B. [Microbiological and molecular genetic aspects of antibiotic resistance of pseudomonas aeruginosa and Acinetobacter baumannii]. Epidemiology and Vaccinal Prevention 2019; 18(6):34–38 (in Russian). https://doi:10.31631/2073-3046-2019-18-6-34-38

2. Tiku V. Acinetobacter baumannii: Virulence strategies and host defense mechanisms. DNA Cell Biol. 2022; 41(1):43- 8. https://doi.org/10.1089/dna.2021.0588

3. Beijerinck M.W. Pigments as products of oxidation by bacterial action. Proc. Royal Acad. Sci. (Amsterdam). 1911; 13:1066–1077.

4. Buchanan R.E., Gibbons N.E. Bergey’s manual determinative bacteriology. Baltimore: Williams & Wilkins Co; 1974.

5. Avramenko A.A. [Acinetobacter baumannii – why such a name?] (in Russian). Available at: https://amrhub.ru/blog/2024/03/13/ety-baumannii/#_ftn2

6. Chebotar I.V., Lazareva A.V., Masalov Ya.K., Mikhailovich V.M., Mayanskiy N.A. [Acinetobacter: microbiologic, pathogenetic and resistance properties]. Annals of the Russian Academy of Medical Sciences 2014; 69(9-10):39–50. https://doi.org/10.15690/vramn.v69i9-10.1130

7. Boone D.R., Castenholz R.W., Garrity G.M., editors. Bergey’s Manual of Systematic Bacteriology. New York: Springer. URL: http://www.bergeys.org/outlines.html

8. Kisil O.V., Efimenko T.А., Gabrielyan N.I., Efremenkova O.V. [Development of antimicrobial therapy methods to overcome the antibiotic resistance of Acinetobacter baumannii]. Acta Naturae 2020; 12(3):34–45 (in Russian). https://doi.org/10.32607/actanaturae.10955

9. Peleg A.Y., Seifert H., Paterson D.L. Acinetobacter baumannii: Emergence of a successful pathogen. Clin. Microbiol. Rev. 2008; 21(3):538–582. https://doi.org/10.1128/CMR.00058-07

10. Mea H.J., Yong P.V.C., Wong E.H. An overview of Acinetobacter baumannii pathogenesis: Motility, adherence and biofilm formation. Microbiol. Res. 2021; 247: 126722. https://doi.org/10.1016/j.micres.2021.126722

11. Barantsevich N.E., Ivanova L.V., Barantsevich E.P. [Acinetobacter baumannii: mechanisms of antimicrobial resistance]. Antibiotics and Chemotherapy 2024; 69(11-12):93–100 (in Russian). https://doi.org/10.37489/0235-2990-2024-69-11-12-93-100

12. Goncharova A. R., Gostev V.V., Goncharov N.E., Kalinogorskaya O.S., Gladyshev N.S. [Antibacterial therapy options for infections caused by carbapenem-resistant Acinetobacter baumannii]. Antibiotics and Chemotherapy 2024; 69(7- 8):53–66 (in Russian). https://doi.org/10.37489/0235-2990-2024-69-7-8-53-66

13. Falagas M.E., Rafailidis P.I. Attributable mortality of Acinetobacter baumannii: no longer a controversial issue. Crit. Care. 2007; 11(3):134. https://doi.org/10.1186/cc5911

14. Dijkshoorn, L., Nemec A., Seifert H. An increasing threat in hospitals: Multidrug-resistant Acinetobacter baumannii. Nat. Rev. Microbiol. 2007; 5(12):939–951. https://doi.org/10.1038/nrmicro1789

15. Howard A., O'Donoghue M., Feeney A., Sleator R.D. Acinetobacter baumannii: an emerging opportunistic pathogen. Virulence 2012; 3(3):243–250. https://doi.org/10.4161/viru.19700

16. Centers for Disease Control and Prevention (CDC). Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002-2004. MMWR Morb. Mortal. Wkly Rep. 2004; 53(45):1063– 1066.

17. Grigoryevskaya Z.V., Dmitrieva N.V., Petukhova I.N., Dyakova S.А. [Infectious complications caused by pandrug resistant strain of Acinetobacter baumanii in cancer patients]. Siberian Journal of Oncology 2011; 6:14–18 (in Russian).

18. Dmitrieva N.V., Grigoryevskaya Z.V., Dyakova S.А., Klyuchnikova I.А., Petuchova I.N. [Development of strategic approaches to therapy of infections caused by multiresistant Аcinetobacter baumannii]. Siberian Journal of Oncology 2012; 4(52):11–19 (in Russian).

19. Centers for Disease Control and Prevention (CDC). (Update 2019). Available at: https://search.cdc.gov/search/?query=Acinetobacter

20. Gudueva E.N., Chemisova O.S. [Pathogenicity factors of Acinetobacter baumannii]. Meditsinskiy vestnik Yuga Rossii = Medical Herald of the South of Russia 2023; 14(1):66–74 (in Russian). https://doi.org/10.21886/2219-8075-2023-14-1-66-74

21. Sadeeva Z.Z., Novikova I.E., Alyabyeva N.M., Lazareva A.V., Komyagina T.M., Karaseva O.V., Vershinina M.G., Fisenko A.P. [Acinetobacter baumannii in blood-borne and central nervous system infections in intensive care unit children: molecular and genetic characteristics and clinical significance]. Infektsiya i immunitet = Russian Journal of Infection and Immunity 2023; 3(2):289–301 (in Russian). https://doi.org/10.15789/2220-7619-ABI-2091

22. Lima W.G., Brito J.C.M., da Cruz Nizer W.S. Ventilator-associated pneumonia (VAP) caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19: Two problems, one solution? Med. Hypotheses. 2020; 144:110139. https://doi.org/10.1016/j.mehy.2020.110139

23. Petrosillo N., Drapeau C.M., Di Bella S. Acinetobacter Infections. In: Ergönül Ö., Can F., Madoff L., Akova M., editors. Emerging infectious disease. Clinical Case Studies. Amsterdam: Elsevier Acad. Press.; 2014:255–272. https://doi.org/10.1016/C2012-0-07077-9

24. Kotay S., Chai W., Guilford W., Barry K., Mathers A.J. Spread from the sink to the patient: in situ study using green fluorescent protein (GFP)-expressing Escherichia coli to model bacterial dispersion from hand-washing sink-trap reservoirs. Appl. Environ. Microbiol. 2017; 83(8):e03327-16. https://doi.org/10.1128/AEM.03327-16

25. Ge Y.L., Shan Q.W., Qiu Y., Zhou S.P., Cheng Y.B., Wang F., Yang J.W., Wan C.M., Zhu Y., Xu Y., Chen M.X., Lin D.J., Zhu C.H., Zeng M. [Risk factors and resistance patterns of invasive Acinetobacter baumannii infection in Children]. Zhonghua er ke za zhi = Chinese journal of pediatrics 2022; 60(8):762–768 (in Chinese). https://doi.org/10.3760/cma.j.cn112140-20220502-00404

26. Thorarinsdottir H.R., Kander T., Holmberg A., Petronis S., Klarin B. Biofilm formation on three different endotracheal tubes: a prospective clinical trial. Crit. Care. 2020; 24(1):382. https://doi.org/10.1186/s13054-020-03092-1

27. Aedh A.I., Al-Swedan A.D., Mohammed A.A., Alwadai B.M., Alyami A.Y., Alsaaed E.A., Almurdhimah N.M., Zaki M.S., Othman A.E., Hasan A. Occurrence of multidrug-resistant strains of Acinetobacter spp.: an emerging threat for nosocomial- borne infection in Najran region, KSA. Trop. Med. Infect. Dis. 2023; 8:108. https://doi.org/10.3390/tropicalmed8020108

28. Noskov A.K., Popova A.Yu., Vodop’ianov A.S., Pisanov R.V., Chemisova O.S., Pavlovich N.V., Demina Yu.V., Gudueva E.N., Kovalev E.V., Karpushchenko G.V. [Molecular genetic analysis of the causative agents of COVID-19–associated bacterial pneumonia in hospitals of Rostov-on-Don]. Zdorov’e Naseleniya i Sreda Obitaniya 2021; 29(12):64–71 (in Russian). https://doi.org/10.35627/2219-5238/2021-29-12-64-71

29. Nasr P. Genetics, epidemiology, and clinical manifestations of multidrug resistant Acinetobacter baumannii. J. Hosp. Infect. 2020; 104(1):4–11. https://doi.org/10.1016/j.jhin.2019.09.021

30. Kataeva L.V., Kolotova O.N., Stepanova T.F., Kislichkina A.A., Shishkina L.A., Mukhina T.N. [Whole genome sequencing of Acinetobacter baumannii strains isolated from hospital patients in the northern territories of the Tyumen region]. Journal of Microbiology Epidemiology Immunobiology 2022; 99(3):343–352 (in Russian). https://doi.org/10.36233/0372-9311-231

31. Wong D., Nielsen T.B., Bonomo R.A., Pantapalangkoor P., Luna B., Spellberg B. Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges. Clin. Microbiol. Rev. 2017; 30(1):409–447. https://doi.org/10.1128/CMR.00058-16

32. Lavrinenko A.V. [Virulent Acinetobacter baumannii]. Meditsina i ekologiya 2019; 3(32):24–29 (in Russian).

33. Choi C.H., Lee E.Y, Lee Y.C., Park T.I., Kim H.J., Hyun S.H., Kim S.A., Lee S.K., Lee J.C. Outer membrane protein 38 of Acinetobacter baumannii localizes to the mitochondria and induces apoptosis of epithelial cells. Cell. Microbiol. 2005; 7(8):1127–1138. https://doi.org/10.1111/j.1462-5822.2005.00538.x

34. Smani Y., Fàbrega A., Roca I., Sánchez-Encinales V., Vila J., Pachón J. Role of OmpA in the multidrug resistance phenotype of Acinetobacter baumannii. Antimicrob. Agents Chemother. 2014; 58(3):1806–1808. https://doi.org/10.1128/AAC.02101-13

35. Harding C.M., Hennon S.W., Feldman M.F. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nat. Rev. Microbiol. 2018; 16(2):91–102. https://doi.org/10.1038/nrmicro.2017.148

36. de Campos P.A., Royer S., Batistão D.W., Araújo B.F., Queiroz L.L., de Brito C.S., Gontijo-Filho P.P., Ribas R.M. Multidrug resistance related to biofilm formation in Acinetobacter baumannii and Klebsiella pneumoniae clinical strains from different pulsotypes. Curr. Microbiol. 2016; 72(5):617–627. https://doi.org/10.1007/s00284-016-0996-x

37. Kwon S.O., Gho Y.S., Lee J.C., Kim S.I. Proteome analysis of outer membrane vesicles from a clinical Acinetobacter baumannii isolate. FEMS Microbiol. Lett. 2009; 297(2):150–156. https://doi.org/10.1111/j.1574-6968.2009.01669.x

38. Alcoforado Diniz J., Liu Y.C., Coulthurst S.J. Molecular weaponry: diverse effectors delivered by the Type VI secretion system. Cell. Microbiol. 2015; 17(12):1742–1751. https://doi.org/10.1111/cmi.12532

39. Bendinelli M., Friedman H., Bergogne-Berezin E., editors. Acinetobacter biology and pathogenesis. New York: Springer; 2008.

40. Sheldon J.R., Skaar E.P. Acinetobacter baumannii can use multiple siderophores for iron acquisition, but only acinetobactin is required for virulence. PLoS Pathog. 2020; 16(10):e1008995. https://doi.org/10.1371/journal.ppat.1008995

41. Kuznetsova D.A., Rykova V.A., Podladchikova O.N. [Bacterial siderophores: structure, functions, and role in the pathogenesis of infections]. Problemy Osobo Opasnykh Infektsii = Problems of Particularly Dangerous Infections 2022; 3:14–22 (in Russian). https://doi.org/10.21055/0370-1069-2022-3-14-22

42. Touchon M., Cury J., Yoon E.J., Krizova L., Cerqueira G.C., Murphy C., Feldgarden M., Wortman J., Clermont D., Lambert T., Grillot-Courvalin C., Nemec A., Courvalin P., Rocha E.P. The genomic diversification of the whole Acinetobacter genus: origins, mechanisms, and consequences. Genome Biol. Evol. 2014; 6(10):2866–2882. https://doi.org/10.1093/gbe/evu225

43. Johnson TL., Waack U., Smith S., Mobley H., Sandkvist M. Acinetobacter baumannii is dependent on the type II secretion system and its substrate LipA for lipid utilization and in vivo fitness. J. Bacteriol. 2015; 198(4):711–719. https://doi.org/10.1128/JB.00622-15

44. Weber B.S., Miyata S.T., Iwashkiw J.A., Mortensen B.L., Skaar E.P., Pukatzki S., Feldman M.F. Genomic and functional analysis of the type VI secretion system in Acinetobacter. PLoS One 2013; 8(1):e55142. https://doi:10.1371/journal.pone.0055142

45. Bentancor L.V., Camacho-Peiro A., Bozkurt-Guzel C., Pier G.B., Maira-Litrán T. Identification of Ata, a multifunctional trimeric autotransporter of Acinetobacter baumannii. J. Bacteriol. 2012; 194(15):3950–3960. https://doi.org/10.1128/JB.06769-11

46. Lin Q., Deslouches B., Montelaro R.C., Di Y.P. Prevention of ESKAPE pathogen biofilm formation by antimicrobial peptides WLBU2 and LL37. Int. J. Antimicrob. Agents 2018; 52(5):667–672. https://doi.org/10.1016/j.ijantimicag.2018.04.019

47. Espinal P., Martí S., Vila J. Effect of biofilm formation on the survival of Acinetobacter baumannii on dry surfaces. J. Hosp. Infect. 2012; 80(1):56–60. https://doi.org/10.1016/j.jhin.2011.08.013

48. Roca I., Espinal P., Vila-Farrés X., Vila J. The Acinetobacter baumannii oxymoron: commensal hospital dweller turned pan-drug-resistant menace. Front. Microbiol. 2012; 3:148. https://doi.org/10.3389/fmicb.2012.00148

49. Mikhailovich V.M., Heydarov R.N., Bocharova J.A., Chebotar I.V. [Molecular-genetic portrait of virulence of Stenotrophomonas maltophilia]. Journal of Microbiology Epidemiology Immunobiology 2023; 100(5):422–432 (in Russian). https://doi.org/10.36233/0372-9311-417

50. Roca S., Al-Saryi N., Al-Kadmy I.M.S., Aziz S.N. Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals. Mol. Biol. Rep. 2021; 48 (10):6987–6998. https://doi.org/10.1007/s11033-021-06690-6

51. Shelenkov A., Akimkin V., Mikhaylova Y. International clones of high risk of Acinetobacter baumannii – definitions, history, properties and perspectives. Microorganisms 2023; 11(8):2115. https://doi.org/10.3390/microorganisms11082115

52. Gorbich Yu.L., Karpov I.A., Krechikova O.I. [Acinetobacter baumannii infections: risk factors, diagnosis, treatment, prevention approaches]. Meditsinskie novosti 2011; 5:31–39 (in Russian).

53. Dexter C., Murray G.L., Paulsen I.T., Peleg A.Y. Community-acquired Acinetobacter baumannii: clinical characteristics, epidemiology and pathogenesis. Expert Rev. Anti Infect. Ther. 2015; 13(5):567–573. https://doi.org/10.1586/14787210.2015.1025055

54. Alekseeva E.I., Slobodenyuk A.V. [Some features of the epidemic process of nosocomial infections in pediatric burn units]. Ural′skiy meditsinskiy zhurnal 2007; 11:93–95 (in Russian).

55. Garnacho-Montero J, Amaya-Villar R, Ferrándiz-Millón C, Díaz-Martín A, López-Sánchez JM, Gutiérrez-Pizarraya A. Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia. Expert Rev. Anti Infect. Ther. 2015; 13(6):769–777. https://doi.org/10.1586/14787210.2015.1032254

56. Geisinger E., Isberg R.R. Antibiotic modulation of capsular exopolysaccharide and virulence in Acinetobacter baumannii. PLoS Pathog. 2015; 11(2):e1004691. https://doi.org/10.1371/journal.ppat.1004691

57. Khazaal S.S, Al-Saryi N., Ibrahim S.A. Immunomodulation by Acinetobacter baumannii of endotracheal tube biofilm in ventilator-associated pneumonia. Meta Gene 2020; 13:100672. https://doi.org/10.1016/j.mgene.2020.100672

58. Popova A.Yu., Ezhlova E.B., Demina Yu.V., Noskov A.K., Kovalev E.V., Karpushchenko G.V., Chemisova O.S., Pichurina N.L., Pavlovich N.V., Vodopyanov S.O., Gudueva E.N., Slis S.S., Pshenichnaya N.Yu., Litovko A.R., Asmolova N.Yu. [Etiology of community-acquired pneumonia during the epidemic spread of COVID-19 and healthcare-associated pneumonia risk assessment]. Zdorov’e Naseleniya i Sreda Obitaniya – ZNiSO = Public Health and Life Environment 2021; (7):67–75 (in Russian). https://doi.org/10.35627/2219-5238/2021-29-7-67-7591

59. Chopra T., Marchaim D., Awali R.A., Krishna A., Johnson P., Tansek R., Chaudary K., Lephart P., Slim J., Hothi J., Ahmed H., Pogue J.M., Zhao J.J., Kaye K.S. Epidemiology of bloodstream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin/sulbactam on clinical outcomes. Antimicrob. Agents Chemother. 2013; 57(12):6270–6275. https://doi.org/10.1128/AAC.01520-13

60. Jean S.S., Hsueh P.R. High burden of antimicrobial resistance in Asia. Int. J. Antimicrob. Agents 2011; 37(4):291– 295. https://doi.org/10.1016/j.ijantimicag.2011.01.009

61. Cavallo I., Oliva A., Pages R., Sivori F., Truglio M., Fabrizio G. Pasqua M., Pimpinelli F., Di Domenico E.G. Acinetobacter baumannii in the critically ill: complex infections get complicated. Front. Microbiol. 2023; 14:1196774 https://doi.org/10.3389/fmicb.2023.1196774

62. Vincent J.L., Rello J., Marshall J., Silva E., Anzueto A., Martin C.D., Moreno R., Lipman J., Gomersall C., Sakr Y., Reinhart K. EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302(21):2323–2329. https://doi.org/10.1001/jama.2009.1754

63. Sievert D.M., Ricks P., Edwards J.R., Schneider A., Patel J., Srinivasan A., Kallen A., Limbago B., Fridkin S. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2009-2010. Infect. Control. Hosp. Epidemilol. 2013; 34(1):1–14. https://doi.org/10.1086/668770

64. Antimicrobial resistance surveillance in Europe (Update 2016). Available at: http://www.ecdc.europa.eu

65. European Centre for Disease Prevention and Control. Carbapenemase-producing bacteria in Europe. Technical Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2013. Available at: https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/antimicrobial-resistance-carbapenemase-producing-bacteria-europe.pdf

66. Lee C.R., Lee J.H., Park M., Park K.S., Bae I.K., Kim Y.B., Cha C.J., Jeong B.C., Lee S.H. Biology of Acinetobacter baumannii: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Front. Cell. Infect. Microbiol. 2017; 7:55. https://doi.org/10.3389/fcimb.2017.00055

67. Kyriakidis I., Vasileiou E., Pana Z.D., Tragiannidis A. Acinetobacter baumannii antibiotic resistance mechanisms. Pathogens 2021; 10(3):373. https://doi.org/10.3390/pathogens10030373

68. Khokhlova О.Е., Larionova I.A., Peryanova O.V., Kozlov R.S., Eidelshtein M.V., Modestov A.A., Eremeeva O.G., Lazareva I.V., Akusheva D.N., Lobova T.I., Potkina N.K., Sidorenko S.V., Yamamoto T. [The mechanisms of antibiotic resistance in major pathogens of purulent-inflammatory complications in cancer patients]. Infektsiya i immunitet = Russian Journal of Infection and Immunity 2021; 11(2):324–336 (in Russian). https://doi.org/10.15789/2220-7619-TMO-1379

69. Gudueva E.N., Chemisova O.S., Lychman V.A., Temyakova S.Yu., Poleeva M.V., Noskov A.K., Logvin F.V. [Antimicrobial resistance of Acinetobacter baumannii]. Klinicheskaya laboratornaya diagnostika = Russian Clinical Laboratory Diagnostics 2024; 69 2):97–103 (in Russian). https://doi.org/10.51620/0869-2084-2024-69-2-97-103

70. Tommasi R., Brown D.G., Walkup G.K., Manchester J.I., Miller A.A. ESKAPEing the labyrinth of antibacterial discovery. Nat. Rev. Drug. Discov. 2015; 14(8):529–542. https://doi.org/10.1038/nrd4572

71. EUCAST. Expected Resistant Phenotypes (Update 2023). Available at: https://www.eucast.org/expert_rules_and_expected_phenotypes

72. Lupo A., Haenni M., Madec J. Antimicrobial resistance in Acinetobacter spp. and Pseudomonas spp. Microbiol. Spectr. 2018; 6(3):10.1128/microbiolspec.arba-0007-2017. https://doi.org/10.1128/microbiolspec.arba-0007-2017

73. Djahanschiri B., Di Venanzio G., Distel J.S., Breisch J., Dieckmann M.A., Goesmann A., Averhoff B., Göttig S., Wilharm G., Feldman M.F., Ebersberger I. Evolutionarily stable gene clusters shed light on the common grounds of pathogenicity in the Acinetobacter calcoaceticus-baumannii complex. PLoS Genet. 2022; 18(6):e1010020. https://doi.org/10.1371/journal.pgen.1010020

74. Dmitrieva N.V., Eidelshtein М.V., Aginova V.V., Grigorievskaya Z.V., Petukhova I.N., Tereshchenko I.V., Bagirova N.S., Dyakova S.A., Kalinchuk T.A., Dmitrieva А.I., Shek E.A., Skleenova Е.Yu. [Infections caused by Acinetobacter baumannii in cancer patients]. Siberian Journal of Oncology 2019; 18(3):26–33 (in Russian). https://doi.org/10.21294/1814-4861-2019-18-3-26-33

75. Bykov А.О., Suvorova M.P., Protsenko D.N., Yakovlev S.V., Ignatenko O. V., Burmistrova E.N., Sychev I.N., Krotenko N.P. [Analysis of the structure of bacteremia and sensitivity to antibiotics of microorganisms isolated in intensive care units in an emergency hospital in the period from 2003 to 2021: a retrospective observational study]. Annals of Critical Care 2023; 2:55–65 (in Russian). https://doi.org/10.21320/1818-474X-2023-2-55-65

76. Perez F., El Chakhtoura N.G., Yasmin M., Bonomo R.A. Polymyxins: to combine or not to combine? Antibiotics (Basel) 2019; 8(2):38. https://doi.org/10.3390/antibiotics8020038

77. Tapalski D.V., Bonda N.A. [Acinetobacter baumannii: prevalence, spectrum and dynamics of antimicrobial resistance, susceptibility to antibiotic combinations]. Zhurnal Grodnenskogo gosudarstvennogo meditsinskogo universiteta = Journal of the Grodno State Medical University 2018; 16(3): 286–291 (in Russian). https://doi.org/10.25298/2221-8785-2018-16-3-286-291

78. Bogaerts P., Naas T., Wybo I., Bauraing C., Soetens O., Piérard D., Nordmann P., Glupczynski Y. Outbreak of infection by carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-58 in Belgium. J. Clin. Microbiol. 2006; 44(11):4189–4192. https://doi.org/10.1128/JCM.00796-06

79. Saranathan R., Vasanth V., Vasanth T., Shabareesh P.R., Shashikala P., Devi C.S., Kalaivani R., Asir J., Sudhakar P., Prashanth K. Emergence of carbapenem non-susceptible multidrug resistant Acinetobacter baumannii strains of clonal complexes 103B and 92B harboring OXA type carbapenemases and metallo-β-lactamases in Southern India. Microbiol. Immunol. 2015; 59(5):277–284. https://doi.org/10.1111/1348-0421.12252

80. Rotanov S.V., Akinshina Yu.A., Gashenko T.Yu. Technology for determining carbapenemases in human pathogens using the immunochromatographic method. Klinicheskaya Laboratornaya Diagnostika = Russian Clinical Laboratory Diagnostics 2024; 69(10):520-529 (in Russian). https://doi.org/10.15620/0869-2084-2024-69-10-520-529

81. Butler M.S., Gigante V., Sati H., Paulin S., Al-Sulaiman L., Rex J.H., Fernandes P, Arias C.A., Paul M., Thwaites G.E., Czaplewski L., Alm R.A., Lienhardt C., Spigelman M, Silver L.L., Ohmagari N., Kozlov R., Harbarth S., Beyer P. Analysis of the clinical pipeline of treatments for drug-resistant bacterial infections: despite progress, more action is needed. Antimicrob. Agents Chemother. 2022; 66(3):e0199121. https://doi.org/10.1128/AAC.01991-21

82. Jung S.Y., Lee S.H., Lee S.Y., Yang S., Noh H., Chung E.K., Lee J.I. Antimicrobials for the treatment of drugresistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis. Crit. Care 2017; 21(1):319. https://doi.org/10.1186/s13054-017-1916-6

83. Zavascki A.P., Bulitta J.B., Landersdorfer C.B. Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Rev. Anti Infect. Ther. 2013; 11(12):1333–1353. https://doi.org/10.1586/14787210.2013.845523

84. Mulani M.S., Kamble E.E., Kumkar S.N., Tawre M.S., Pardesi K.R. Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: a review. Front. Microbiol. 2019; 10:539. https://doi.org/10.3389/fmicb.2019.00539

85. Petrosillo N., Ioannidou E., Falagas M.E. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin. Microbiol. Infect. 2008; 14(9):816–827. https://doi.org/10.1111/j.1469-0691.2008.02061.x

86. Motaouakkil S., Charra B., Hachimi A., Nejmi H., Benslama A., Elmdaghri N., Belabbes H., Benbachir M. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J. Infect. 2006; 53(4):274–258. https://doi.org/10.1016/j.jinf.2005.11.019

87. Penwell W.F, Shapiro A.B., Giacobbe R.A., Gu R.F., Gao N., Thresher J., McLaughlin R.E., Huband M.D., DeJonge B.L., Ehmann D.E., Miller A.A. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrob. Agents Chemother. 2015; 59(3):1680–1689. https://doi.org/10.1128/AAC.04808-14

88. АMRmap. [Online Antimicrobial resistance data Analysis Platform in Russia]. Available at: https://amrmap.ru/.

89. Russo A., Bruni A., Gullì S., Borrazzo C., Quirino A., Lionello R., Serapide F., Garofalo E., Serraino R., Romeo F., Marascio N., Matera G., Longhini F., Trecarichi E.M., Torti C. Efficacy of cefiderocol – vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19. Int. J. Antimicrob. Agents 2023; 62(1):106825. https://doi.org/10.1016/j.ijantimicag.2023.106825

Review

For citations:

Golubeva A.O., Bondarenko A.P., Trotsenko O.E., Ogienko O.N. The role of Acinetobacter baumannii in infectious pathology (literature review). Bulletin Physiology and Pathology of Respiration. 2025;(97):160-177. (In Russ.) https://doi.org/10.36604/1998-5029-2025-97-160-177

JATS XML

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1998-5029 (Print)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Bulletin Physiology and Pathology of Respiration

The role of Acinetobacter baumannii in infectious pathology (literature review)

Full Text:

Abstract

Keywords

About the Authors

References

Review

For citations:

Cookies policy